LAUSR

Significant advances in the drug development of indolent non-Hodg-kin lymphoma (iNHL) occurred over the last years expanding the landscape of treatment options. Several novel agents have been approved by the US Food and Drug Administration in iNHL allowing clinicians to limiting the use of cytotoxic chemotherapy. Indications for therapy and criteria for enrollment in iNHL vary across studies with trials accruing based on multiple or specific histologies and on need for therapy. Indications for therapy in iNHL vary between studies with some allowing investigator-based assessment and some with more precise requirements such as the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria to better select those patients in need for immediate therapy. Importantly, GELF criteria were developed for nodal follicular